Reappraisal of the Risks and Benefits of Major Liver Resection in Patients With Initially Unresectable Colorectal Liver Metastases

被引:60
作者
Cauchy, Francois [1 ]
Aussilhou, Beatrice [1 ]
Dokmak, Safi [1 ]
Fuks, David [1 ]
Gaujoux, Sebastien [1 ]
Farges, Olivier [1 ]
Faivre, Sandrine [2 ]
Lepille, Daniel [3 ]
Belghiti, Jacques [1 ]
机构
[1] Beaujon Hosp, Dept HPB Surg & Liver Transplantat, F-92110 Clichy, France
[2] Beaujon Hosp, Dept Oncol, F-92110 Clichy, France
[3] Clin Pasteur, Dept Oncol, Evreux, France
关键词
chemotherapy; colorectal liver metastasis; initial unresectability; portal vein embolization; OXALIPLATIN-BASED CHEMOTHERAPY; LONG-TERM SURVIVAL; 2-STAGE HEPATECTOMY; HEPATIC RESECTION; POSTOPERATIVE MORBIDITY; REPEAT HEPATECTOMY; CANCER; SURGERY; CONTRAINDICATION; RECURRENCE;
D O I
10.1097/SLA.0b013e3182738204
中图分类号
R61 [外科手术学];
学科分类号
100210 [外科学];
摘要
Objectives: To determine short- and long-term outcomes of major hepatectomy in patients with downstaged colorectal liver metastases considered initially unresectable (IU). Background: Improvements in both surgical technique and efficacy of chemotherapy have increased the rate of resection for IU colorectal liver metastases. The outcome of these patients needs to be reassessed. Patients and Methods: From 2000 to 2011, 257 patients underwent major hepatectomy for colorectal liver metastases. Of these, 87 (34%) IU patients required portal vein occlusion after chemotherapy downstaging. Patients requiring less than 12 cycles and 12 or more cycles of chemotherapy before resection were defined as fast responders and slow responders, respectively. Results: Compared with fast responders, slow responders had increased mortality (0% vs 19%, P = 0.003) and major morbidity rates (20% vs 55%, P < 0.001) despite almost identical tumor characteristics and similar procedures. In multivariate analysis, the only factor associated with increased major morbidity was the existence of a number of chemotherapy cycles of 12 or more (hazard ratio [HR]: 5.32, confidence interval [CI]: 1.69-16.7, P = 0.004). One-, 3-, and 5-year disease-free survival rates for the entire population were 48%, 17.5%, and 13%, respectively. Multivariate analysis found that slow responders (HR: 2.89, CI: 1.67-5.04, P < 0.001) and patients without adjuvant chemotherapy (HR: 2.38, CI: 1.33-4.35, P = 0.004) had a significantly decreased disease-free survival. All slow responders postoperatively recurred within 3 years. Conclusions: Liver resection in slow responders, that is, IU patients requiring 12 or more chemotherapy cycles and portal vein occlusion to achieve resectability, is associated with poor short- and long-term outcomes. These patients would probably benefit from more conservative strategies.
引用
收藏
页码:746 / 754
页数:9
相关论文
共 40 条
[1]
Tumor progression while on chemotherapy - A contraindication to liver resection for multiple colorectal metastases? [J].
Adam, R ;
Pascal, G ;
Castaing, D ;
Azoulay, D ;
Delvart, V ;
Paule, B ;
Levi, F ;
Bismuth, H .
ANNALS OF SURGERY, 2004, 240 (06) :1052-1064
[2]
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[3]
Repeat hepatectomy for colorectal liver metastases [J].
Adam, R ;
Bismuth, H ;
Castaing, D ;
Waechter, F ;
Navarro, F ;
Abascal, A ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1997, 225 (01) :51-60
[4]
Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[5]
Liver resection for colorectal metastases - The third hepatectomy [J].
Adam, R ;
Pascal, G ;
Azoulay, D ;
Tanaka, K ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2003, 238 (06) :871-883
[6]
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].
Alberts, SR ;
Horvath, WL ;
Stcrnfeld, WC ;
Goldberg, RM ;
Mahoney, MR ;
Dakhil, SR ;
Levitt, R ;
Rowland, K ;
Nair, S ;
Sargent, DJ ;
Donohue, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249
[7]
Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab [J].
Aussilhou, Beatrice ;
Dokmak, Safi ;
Faivre, Sandrine ;
Paradis, Valerie ;
Vilgrain, Valerie ;
Belghiti, Jacques .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (06) :1553-1559
[8]
Risk Factors for Liver Failure and Mortality After Hepatectomy Associated With Portal Vein Resection [J].
Bachellier, Philippe ;
Rosso, Edoardo ;
Pessaux, Patrick ;
Oussoultzoglou, Elie ;
Nobili, Cinzia ;
Panaro, Fabrizio ;
Jaeck, Daniel .
ANNALS OF SURGERY, 2011, 253 (01) :173-179
[9]
The "50-50 criteria" on postoperative day 5 - An accurate predictor of liver failure and death after hepatectomy [J].
Balzan, S ;
Belghiti, J ;
Farges, O ;
Ogata, S ;
Sauvanet, A ;
Delefosse, D ;
Durand, F .
ANNALS OF SURGERY, 2005, 242 (06) :824-829
[10]
Continuous versus intermittent portal triad clamping for liver resection -: A controlled study [J].
Belghiti, J ;
Noun, R ;
Malafosse, R ;
Jagot, P ;
Sauvanet, A ;
Pierangeli, F ;
Marty, J ;
Farges, O .
ANNALS OF SURGERY, 1999, 229 (03) :369-375